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ABSTRACT
Objectives To assess the prevalence of statistically 
significant treatment effects, adverse events and small- 
study effects (when small studies report more extreme 
results than large studies) and publication bias (over- 
reporting of statistically significant results) across medical 
specialties.
Design Large meta- epidemiological study of treatment 
effects from the Cochrane Database of Systematic 
Reviews.
Methods We investigated outcomes from 57 162 studies 
from 1922 to 2019, and overall 98 966 meta- analyses 
and 5534 large meta- analyses (≥10 studies). Egger’s and 
Harbord’s tests to detect small- study effects, limit meta- 
analysis and Copas selection models to bias- adjust effect 
estimates and generalised linear mixed models were used 
to analyse one of the largest collections of evidence in 
medicine.
Results Medical specialties showed differences in the 
prevalence of statistically significant results of efficacy and 
safety outcomes. Treatment effects from primary studies 
published in high ranking journals were more likely to be 
statistically significant (OR=1.52; 95% CI 1.32 to 1.75) 
while randomised controlled trials were less likely to report 
a statistically significant effect (OR=0.90; 95% CI 0.86 to 
0.94). Altogether 19% (95% CI 18% to 20%) of the large 
meta- analyses showed evidence for small- study effects, 
but only 3.9% (95% CI 3.4% to 4.4%) showed evidence 
for publication bias after further assessment of funnel 
plots. Adjusting treatment effects resulted in overall less 
evidence for efficacy.
Conclusions These results suggest that reporting of 
large treatment effects from small studies may cause 
greater concern than publication bias. Incentives should be 
created so that studies of the highest quality become more 
visible than studies that report more extreme results.
INTRODUCTION
Publication bias is a major concern in clinical 
research as it affects the combined effects 
from meta- analyses of intervention studies 
and distorts the overall evidence for the effi-
cacy of a treatment.1 2 The problem was already 
characterised more than half a century ago3 
and a number of studies provided compelling 
evidence for publication bias by following 
studies from protocol approval until the 
publication of outcomes.4 5 The problem 
originates when studies with a null result 
are not considered worthy to be written up 
and submitted by researchers, or may not be 
treated favourably in peer review; hence, are 
less likely to be published.6 7 Moreover, statis-
tically significant studies are more likely to 
be published in journals with a high citation 
impact factor8 and get more citations.9 Thus, 
statistically significant results receive more 
attention than null (non- significant) results.
Many countries and medical journal 
publishers require trial registration with the 
aim to prevent publication bias, for example, 
the International Committee of Medical 
Journal Editors. Since 2007 the US Food 
and Drug Administration Amendments Act 
(FDAAA) demands that interventional clin-
ical trials report their results directly to the 
US trial registry ‘ ClinicalTrials. gov’ within 
Strengths and limitations of this study
 ► This is one of the few studies providing a large- 
scale assessment of treatment effects, small- study 
effects and publication bias across different medical 
specialties.
 ► Many methods are available to assess small- study 
effects and publication bias. We only considered 
Egger’s test and Harbord’s test; however, these were 
among the most widely recommended ones.
 ► Bias may be underestimated as the methods used 
in this study have low statistical power; thus, only 
a subset of large meta- analyses (≥10 studies) were 
considered.
 ► The assessment of small- study effects is restricted 
to the traditional p<0.05 threshold. However, we ad-
ditionally bias adjusted the effect estimates without 
any thresholding.
 ► The restriction to large meta- analyses (≥10 studies) 
with low heterogeneity (I2  <50) leads to selection 
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1 year of the completion of the study; however, compli-
ance with FDAAA 2007 is poor with 59% of the studies 
not reporting results in time.10 The retrieval process of 
unpublished results can be difficult, time consuming and 
not always successful. Thus, statistical methods can be 
useful to not only assess but also adjust meta- analyses for 
inflated treatment effects and publication bias.
In clinical research multiple studies on the same treat-
ment are conducted, and meta- analyses are the estab-
lished statistical tool to estimate the combined treatment 
effect. Combined effects are essentially weighted averages 
of the study effects with effects from large studies having 
more weight than effects from smaller studies. If there 
is publication bias, smaller studies with null findings will 
be published less likely. This leads to a positive associ-
ation between the SE of effect sizes and the effect size 
itself, known as the small- study effect.11 This association is 
assessed by Egger’s regression and can be shown as asym-
metry in a funnel plot,12 but this method also has some 
limitations.13
The estimate of the correlation between study size and 
effect size may be erroneous if there are few studies, or 
if there is heterogeneity across studies. Even though it is 
often assumed that publication bias may be a plausible 
explanation for small- study effects, there are also other 
possible causes. For example, low- quality studies that 
report inflated effect sizes, or clinical heterogeneity of 
patients when small studies focus on high- risk patients for 
whom the treatment may be more effective. Therefore, 
it is important to follow guidelines when applying such 
methods14 15 such as excluding meta- analyses with high 
heterogeneity or less than 10 studies as they can mislead 
small study tests. Sterne et al14 recommended Harbord’s 
test16 for dichotomous outcomes using ORs and Egger’s 
test12 for continuous outcomes. Also, the Cochrane hand-
book recommends the same tests, provided that there are 
at least 10 studies.17
In contrast to regression methods that assess small- study 
effects, selection models explicitly model publication bias. 
Selection models adjust meta- analytical data by specifying 
a model that describes the mechanism by which effect 
sizes may be suppressed. The Copas selection model18 
is among the more sophisticated selection models19 and 
investigates whether studies with a certain effect size have 
a greater probability to enter a meta- analysis. A common 
feature in both regression- based methods and the Copas 
selection model20 is that effect estimates can be adjusted 
for bias. For example, regression- based adjustments of 
treatment effects were successful in the prediction of the 
effect of antidepressant trials from the FDA trial registry 
using a biased subset of the data.21
There have been other studies on the extent of publica-
tion bias in the Cochrane Database of Systematic Reviews 
(CDSR). Sutton et al22 estimated that around 50% of 48 
Cochrane reviews had missing studies. A large study15 
investigated meta- analyses with binary outcomes and 
found small- study effects in 19% of the 366 meta- analyses. 
Contrarily, another study found no convincing evidence 
for publication bias23 but they only investigated a small 
subset of 83 meta- analyses. A study that used a selection 
model with 1106 meta- analyses found positive findings to 
be 27% more likely to be included in a meta- analysis.24 
An extensive and recent study by Lin et al25 investigated 
30 000 meta- analyses from the CDSR and tested various 
methods among those regression- based tests (but no 
selection models) and reported considerable small- study 
effects in 20%–40% of the meta- analyses; however, they 
included meta- analysis with five studies which is at odds 
with the common guideline of at least 10 studies. Some 
methodological studies have been performed with data 
from the CDSR to evaluate various asymmetry tests and 
found that Egger’s linear regression was most sensitive to 
detect asymmetry.26 27 Statistical power can be increased 
by choosing a more liberal p value threshold with no 
substantial increase in false positive rate,28 and indeed in 
many studies a significance level of p<0.10 was used.
Previous studies were sometimes constrained to only a 
subset of the CDSR data or to methodology that is gener-
ally not recommended.29 Often it was not reported how 
outcomes related to efficacy were distinguished from 
outcomes related to adverse events. This is important 
because publication bias may not operate in favour of 
statistically significant adverse effects. Furthermore, 
adjustment of the effect sizes is rarely performed, and to 
the best of our knowledge, none of the studies compared 
small- study effects and publication bias across different 
medical specialties.
The aim of this study was a large- scale meta- 
epidemiological assessment of the prevalence of statis-
tically significant treatment effects, adverse events, 
small- study effects and publication bias in meta- analyses 
across different medical specialties. The four objectives 
are summarised in more details as follows:
1. Assessment of the reported statistically significant ef-
fect sizes in primary studies.
2. Assessment of the statistically significant combined ef-
fect estimates in meta- analyses.
3. Estimation of small- study effects and publication bias 
in large meta- analyses.
4. Statistical bias adjustment of treatment effect estimates.
The hypotheses were specified in more detail in the 
protocol ( osf. io/ 3a28k) and in the online supplemental 
table 1.
METHODS
A study protocol was written, and the methods were spec-
ified in advance including a statistical analysis plan. The 
protocol was registered on 9 July 2019 ( osf. io/ 3a28k). 
Deviations from the protocol are specified at the end of 
the methods sections. The complete pipeline with anal-
ysis code written in R is available at  osf. io/ uv397. We 
reported this study following the guidelines for meta- 
epidemiological studies30 as well as the Strengthening 
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(STROBE) statement,31 the STROBE checklist for this 
study can be found at  osf. io/ b6gxf.
Search strategy and study selection
Systematic reviews of the type ‘intervention’ were 
selected from the CDSR which were 7931 reviews as of 11 
November 2019. All reviews involved an intervention, for 
example, a drug, a surgical procedure, a psychotherapy, a 
medical device, preventive care, etc.
Data collection
Data from 6075 (77%) of all the systematic reviews could 
be retrieved which comprised 253 430 meta- analyses 
with outcomes from 71 986 primary studies from over 
50 million patients (figure 1A). For each systematic review, 
the data were downloaded from the Cochrane Library as 
an XML file, parsed and aggregated in a large database 
in R. The database included the sample sizes, mean and 
SD (for continuous outcomes) or the number of events 
(for dichotomous outcomes) for both the intervention 
and control arm. We further extended the dataset by 
scraping additional information for the 6075 Cochrane 
reviews: the full reference of the included primary studies 
(including the journal name) and the table ‘characteris-
tics of included studies’ which included additional details 
on the methods, participants, interventions and outcomes 
of the intervention studies. We collected citation informa-
tion from Google Scholar (May 2020;  scholar. google. com) 
for 40 306 (70%) and the Scimago journal ranks (SJR; 
February 2020; www. scimagojr. com) for 39 270 (69%) of 
the primary studies selected for analyses in figure 1B.
Data processing
Beside the outcomes related to the efficacy of an interven-
tion, there were also outcomes related to adverse events 
(13.5%), withdrawal/dropout from the study (2.4%) 
and bias/sensitivity analyses (1.3%). Outcomes related 
to adverse events, withdrawal and bias were identified by 
using a set of keywords and regular expressions on the 
comparison name, outcome name and subgroup name as 
provided by the CDSR.
Figure 1 Selection process from the Cochrane Database of Systematic Reviews (CDSR). (A) Data from 77% of the systematic 
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The 53 Cochrane review groups (which also included 
past groups) were merged into 19 medical specialties, 
see online supplemental table 2. Small groups were 
merged when they contained less than 150 reviews and 
assignment was based on thematic overlap, for example, 
various cancer groups into ‘oncology’, various neurolog-
ical conditions into ‘neurology’.
Inclusion criteria
The data selection process for the analyses conducted 
is shown in figure 1B–D. The analysis of the effect sizes 
(figure 1B) included all effects from published primary 
studies. For the analysis of the combined effects from 
meta- analyses the number of primary studies was at least 
2 (figure 1C). We only considered study effects from 
published sources in the meta- analyses. Meta- analyses 
based on subgroups were generally included as they 
conveyed important evidence (eg, different comparison 
of drugs).
For the small- study effects tests, we followed the inclu-
sion criteria by Ioannidis and Trikalinos.15 Among them 
are at least 10 studies and low to moderate heteroge-
neity (I2 <50%) in the meta- analysis (see figure 1D and 
protocol for details).
Statistical analyses
We used Wilson CIs for proportions and Wald CIs for ORs 
and regression coefficients. Differences in proportions 
across medical specialties were assessed with a Pearson’s 
χ
2 test without continuity correction.
Effect sizes from primary studies
Effect sizes from primary studies included various 
outcome measures. The most common were risk ratios 
(46%), mean differences (26%), ORs (11%) and stan-
dardised mean differences (SMD) (8%). Comparing 
reported effect sizes from primary studies across medical 
specialties required harmonisation. We recalculated all 
effect sizes for the primary studies using escalc() from the 
R package metafor.32 For continuous outcomes the SMD 
(Hedges’ g), for dichotomous outcomes the ORs were 
used. ORs were transformed into Hedges’ g. All effects 
on the common SMD scale were then transformed into 
Pearson’s r.33 An overview of the harmonisation of effect 
estimates from primary studies and meta- analyses and 
associated statistical analyses are shown in online supple-
mental figure 1. Statistical significance was assessed with 
a Wald test which was performed on the original effect 
measure as reported in the CDSR (eg, risk ratio, OR); for 
mean differences we applied a two- sample Student’s t- test.
Combined effect estimates from meta-analyses
We used the R package meta34 for conducting random 
effects meta- analyses (with DerSimonian- Laird estimator 
for between study variance) for continuous outcomes 
(Hedges’ g) and binary outcomes (OR). The combined 
effect from the random effects meta- analysis was converted 
into Pearson’s r33 for comparison across specialties.
Small-study effect tests and adjustment of combined effects
Given the vast number of methods that exist to study 
publication bias and the lack of proper validation,35 we 
restricted our analyses to Egger’s12 and Harbord’s test.16 
For continuous outcomes we used Egger’s regression of 
the effect estimates on their precision (ie, inverse SE). 
Harbor’s test is a modification for ORs that resolves the 
issue of the standard errors not being independent from 
the effect estimates even in the absence of small- study 
effects. Meta- analyses of Peto ORs were performed with 
ORs, and meta- analysis of HRs or risk differences were 
performed with risk ratios instead; tests for risk differ-
ences are not recommended.17 All tests were performed 
one sided (p<0.05); the rationale for this will be explained 
further below.
The metasens package36 was used to adjust combined 
effects via a regression- based method known as limit 
meta- analysis37 38 and the Copas selection model.18 20 Both 
methods are based on a random effects model. The Copas 
selection model is an alternative to regression- based tests 
that explicitly models the chance of publication, that is, 
whether studies with a certain effect size have a greater 
probability to enter a meta- analysis. All adjustments were 
performed on the log ORs for dichotomous outcomes 
and on SMDs for continuous outcomes and were after-
wards transformed to Pearson’s r scale33 in order to 
compare results across medical specialties.
We assessed whether the adjustment increased or 
decreased the evidence for an effect of the interven-
tion. As we were not able to infer the direction of the 
anticipated treatment effect for every meta- analysis, we 
defined the direction in favour of the treatment as the 
sign with more statistically significant study results.23 
Once the anticipated sign of the treatment effect was 
determined, a one- sided regression- based test (p<0.05) 
could be performed which had the advantage to exclude 
situations where asymmetry was not caused by a small- 
study effect.
Small-study effect with probable publication bias
Small- study effect tests do not directly assess publica-
tion bias, and it is important to further evaluate the 
meta- analyses.13 We chose the meta- analyses with signifi-
cant small- study effects (at p<0.05) and determined the 
proportion of studies with a traditionally significant result 
vs a null result in any of the top 50%, 33% and 25% of 
the studies with the largest SEs (ie, among the smallest 
studies). If an equal or larger proportion of statistically 
significant studies were found in any of the quantiles, we 
assumed ‘small- study effects with probable publication 
bias’ as publication bias seemed more likely in such situ-
ations. While publication bias may theoretically still be 
possible and there are ‘hidden’ studies in the funnel plot, 
their impact (magnitude of bias) may not be so severe 
when a majority of the smaller studies that were published 
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Change in evidence for treatment effects
We converted the p values from the combined treatment 
effects from a random effects meta- analysis, from the bias- 
adjusted regression- based analysis and from the Copas 
selection model analysis into Bayes factor bounds39 and 
categorised those into six levels of ‘weak’ to ‘decisive’ 
evidence against the null hypothesis.40 The change in 
evidence after adjustment was determined by comparing 
the proportions of treatment effects falling in those 
categories.
Modelling of outcomes: statistical significance, small-study 
effects and bias adjustment
Six generalised linear mixed- effects models (labelled 1–6 
in the following text) were performed with the R package 
lme441 for the binary outcome statistical significance 
(p<0.05, two sided) of the treatment effects in primary 
studies (1) and combined effects from meta- analyses (2). 
We modelled the evidence for asymmetry using the test 
statistic (t- score) from the regression- based test (3) as 
well as the binary outcome (4) of whether the asymmetry 
tests gave a statistically significant result or not (p<0.05, 
one sided). We also modelled the change in Pearson’s 
r after adjustment with regression- based adjustment (5) 
and Copas adjustment (6). The explanatory variables for 
models 1–6 were specified in the protocol.
Explanatory variables that were right- skewed were log
2
 
transformed. Random effects accounted for dependen-
cies and nesting in the data; these were the study identifier 
to model results from primary studies, and the Cochrane 
review identifier for the meta- analyses. The models were 
in more detail specified in the study protocol section 4.3.
Missing data
There were no missing data for the outcome variables: 
treatment effect from primary studies, combined treat-
ment effect from meta- analyses, assessment of small- study 
effect or adjustment by regression. The Copas adjustment 
of treatment effects was not possible due to numerical 
issues in 143 (2.6%) meta- analyses.
We performed complete- case analysis with some missing 
data in the explanatory variables used in the mixed- effects 
models. For model 1, missing data were in publication 
year (14%), journal rank (31%) and number of citations 
(32%) with a total of 44% of the cases excluded. The 
missing data were due to published studies in journals 
with no journal rank or no citation information available. 
Google Scholar only provides data if the study has at least 
a single citation. For model 2, missing data were in the 
median journal rank (6%) and median number of cita-
tions (11%) with a total of 14% of the cases excluded. For 
models 3–6, missing data were in the median journal rank 
(2%), and median number of citations (3%) with a total 
of 4% of the cases excluded.
Changes from the initial protocol
The following six changes from the initial protocol were 
made. (1) We used a different categorisation into medical 
specialties. According to the protocol we aimed to use 
the 36 topics, but after acquiring the data we found that 
systematic reviews can be assigned to multiple such topics. 
Therefore, we used the 53 Cochrane Review Groups with 
every review assigned to exactly one review group. (2) 
We used the binary outcome of whether the effects were 
statistically significant but did not specify this clearly and 
just used the term ‘effect size’ instead of ‘statistical signif-
icance of effect size’ (protocol section 3: 1c and 2c; 4.3: 
1c and 2c). (3) We specified the regression model for 
hypothesis 2c but we did not list the dependent variable 
in the statistical analysis plan (protocol section 4.3; 2c). 
(4) We were able to add a binary variable randomised 
controlled trial (RCT) (yes/no), that is, whether a study 
was reported as an RCT, and used this additional vari-
able in the modelling (protocol section 4.3; 1c). (5) We 
used categorical quartiles of the journal rank instead of 
the continuous variable (protocol section 4.3; 1c); these 
were provided by Scimago themselves. (6) We applied 
Harbord’s test only for ORs and not generally for all 
binary outcomes as specified in the protocol (protocol 
section 4.4).
Patient and public involvement
There was no patient and public involvement in this study.
RESULTS
Effect sizes from primary studies
Descriptives of primary studies
We analysed a total of 276 904 treatment effects from 
57 162 studies that were published between 1922 and 
2019. Online supplemental tables 3–5 give a detailed 
description of the primary studies per medical specialty 
(number of studies, median sample size, median treat-
ment effect, etc).
Observed statistically significant effects in primary studies
Generally, we observed more statistically significant 
effects for efficacy outcomes than for adverse events with 
the exception of oncology and pregnancy and childbirth 
(figure 2A, online supplemental table 6). The propor-
tions of significant effects in efficacy and safety outcomes 
differed among specialties (both p<0.0001). The largest 
proportion of significant treatment effects were 36% in 
both the specialties skin and wounds (95% CI 0.35 to 
0.38) and anaesthesia and pain (95% CI 0.36 to 0.37); the 
smallest was 18% in neonatology (95% CI 0.18 to 0.19). 
For safety outcomes, the largest proportion was 29% in 
oncology (95% CI 0.27 to 0.31) and the smallest of 8% 
was in emergency and trauma (95% CI 0.07 to 0.10). We 
found no evidence for an association between the propor-
tion of significant effects and the median sample size 
across the medical specialties (figure 2B). We performed 
a p curve analysis and found that all the specialties had a 
right- skewed shape, and no inflation of p values close to 
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Odds for a statistically significant effect reported in a primary 
study
We modelled the binary outcome of whether a reported 
treatment effect was statistically significant. We found that 
the odds for a significant result was highest with a 1.9- fold 
increase in anaesthesia and pain (OR=1.93; 95% CI 1.79 
to 2.08), and lowest with a 38% reduction in pregnancy 
and childbirth (OR=0.62; 95% CI 0.58 to 0.67) compared 
with the mean across specialties, see figure 2C and online 
supplemental table 7. Primary studies published in the 
second, third or fourth journal rank quartiles were all 
associated with higher odds for a statistically significant 
result (compared with the first quartile); the strongest 
effect had the top quartile (Q4) that showed a 1.5- fold 
increase of the odds (OR=1.52; 95% CI 1.32 to 1.75). 
Positive associations with significance were found for log
2
 
study size (OR=1.15; 95% CI 1.14 to 1.17) and log
2
 number 
of citations per year (OR=1.07; 95% CI 1.06 to 1.08) and 
negative associations for publication year (per 10 years; 
OR=0.94; 95% CI 0.92 to 0.96) and when a primary study 
was an RCT (OR=0.90; 95% CI 0.86 to 0.94).
Combined effect estimates from meta-analyses
Descriptives of the meta-analyses
A total of 98 966 random effects meta- analyses were calcu-
lated from 4737 intervention reviews. The largest number 
of meta- analyses were from psychiatry and mental health 
(13 906); and the median total sample size in the meta- 
analyses across studies was N=523 (IQR 220–1395), see 
more descriptives in online supplemental table 8.
Observed statistically significant combined effects in meta-
analyses
The proportion of statistically significant results varied 
across specialties (p<0.0001), the largest was 49% in 
anaesthesia and pain (95% CI 0.47 to 0.50), and the lowest 
was 21% in neonatology (95% CI 0.20 to 0.22), see online 
supplemental table 9. We performed a p curve analysis 
Figure 2 Reported statistically significant results across medical specialties. (A) Proportion (with 95% CI) of reported 
statistically significant effects in published studies for efficacy and safety outcomes. (B) Relationship between the proportion 
of statistically significant effects and the median sample size. ORs (with 95% CI) for a statistically significant effect in a primary 
study (C) and in a combined effect from a meta- analysis (D). RCT, randomised controlled trial. ENT, ear, nose and throat. SJR, 
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and observed that all the specialties had a right- skewed 
shape with no inflation of p values close to p=0.05 (online 
supplemental figure 3).
Odds for a statistically significant effect in a meta-analysis
We modelled the binary outcome of statistical signifi-
cance of the combined effects from the meta- analyses 
(figure 2D and online supplemental table 10). We found 
the highest odds with a 2.5- fold increase in anaesthesia and 
pain (OR=2.46; 95% CI 1.97 to 3.06) and the lowest with 
a 43% reduction in pregnancy and childbirth (OR=0.57; 
95% CI 0.47 to 0.68) compared with the average across 
specialties. The number of studies (log
2
) included in a 
meta- analysis had 1.6- fold higher odds for a statistically 
significant result (OR=1.60; 95% CI 1.56 to 1.65). Positive 
associations with significance had the log
2
 sample size 
(OR=1.08; 95% CI 1.07 to 1.10) and the log
2
 number of 
citations (OR=1.04; 95% CI 1.02 to 1.06). Journal rank 
and review year showed no evidence for an effect.
Small-study effects and publication bias
Prevalence of small-study effects
A total of 5534 meta- analyses from 949 Cochrane system-
atic reviews were assessed that satisfied our inclusion 
criteria. We found small- study effects in 1054 (19%) of 
the meta- analyses (95% CI 18% to 20%) based on Egger’s 
and Harbord’s tests, the distribution of p values is given in 
figure 3A. Infectious diseases had the highest prevalence 
Figure 3 Small- study effects in meta- analyses across medical specialties. (A) Distribution of p values from regression- based 
tests, p<0.05 (one sided) were considered as evidence for small- study effects in meta- analyses (red). (B) Prevalence (with 
95% CI) of small- study effects across the medical specialties. (C) Regression estimates (with 95% CI) for small- study effects 
with the outcome t- scores from regression- based tests. (D) Same but for a binary outcome (small- study effects yes/no). (E) 
Distribution of intercepts (magnitude of small- study effects) from regression- based test. (F) Number of systematic reviews 





















































































































8 Schwab S, et al. BMJ Open 2021;11:e045942. doi:10.1136/bmjopen-2020-045942
Open access 
(35%; 95% CI 25% to 45%) and genetics and endocri-
nology the lowest prevalence (10%; 95% CI 6% to 17%), 
see figure 3B.
Modelling small-study effects
We modelled the test statistic (t- score) from the regression- 
based test for small- study effects (figure 3C and online 
supplemental table 11). Infectious diseases (0.34; 95% CI 
0.02 to 0.66) and anaesthesia and pain (0.30; 95% CI 0.12 
to 0.48) showed larger small- study effects compared with 
the mean across the specialties; lungs showed smaller 
small- study effects (−0.19; 95% CI −0.37 to −0.01). The 
number of studies (log
2
) (0.27; 95% CI 0.22 to 0.33) was 
associated with larger small- study effects, the sample size 
(log
2
) with smaller (−0.04; 95% CI −0.07 to −0.01).
Similar results were obtained for small- study effect 
as binary outcome. Infectious diseases had threefold 
increased odds for small- study effects compared with the 
mean across specialties (OR=3.00; 95% CI 1.26 to 7.16), 
see figure 3D and online supplemental table 12. The 
number of studies (log
2
) included in the meta- analyses 
had twofold higher odds for small- study effects (OR=2.23; 
95% CI 1.89 to 2.63).
Small-study effects with probable publication bias
Meta- analyses with evidence for small- study effects were 
further assessed. From the 1054 meta- analyses with small- 
study effects we identified 214 meta- analyses (20%) 
having small- study effects with probable publication bias 
which was 3.9% (95% CI 3.4% to 4.4%) of the total of 
5534 meta- analyses included. The intercepts from Egger’s 
tests (representing the magnitude of the bias) showed 
more extreme values for meta- analyses with probable 
publication bias than without (figure 3E); 99.5% of these 
were considered as substantial small- study effects based 
on the categorisation by Lin et al.25
Overall, 378 (40%) from 949 Cochrane systematic 
reviews had at least one meta- analysis with small- study 
effects and 115 (12%) reviews had at least one meta- 
analysis that showed small- study effects with probable 
publication bias, see figure 3F for results per medical 
specialty. Examples of small- study effects versus small- 
study effects with probable publication bias are shown in 
figure 4A,B, respectively.
Adjustment of effect estimates from meta-analyses
Regression- based adjustment of the 1054 meta- analyses 
with small- study effects resulted in a reduction of the 
effects in 99% of the cases and the median change in the 
combined effect (Pearsons’s r) was −0.09 (figure 5A). For 
the Copas selection model the reduction was in 77% of 
the cases and the median change was −0.02 (figure 5B).
We applied a mixed- model to all 5534 included 
meta- analyses to find associations with effect change 
after regression- based adjustment and Copas adjust-
ment (figure 5C,D). For the limit meta- analysis based 
on Egger’s test, larger adjustments were required for 
Infectious diseases (−0.05; 95% CI −0.08 to −0.02) and 
anaesthesia and pain (−0.02; 95% CI −0.040 to −0.001). 
Also, Copas required larger adjustments for infectious 
diseases (−0.02; 95% CI −0.027 to −0.006) and anaesthesia 
and pain (−0.01; 95% CI −0.016 to −0.003). Kidney and 
transplant had smaller adjustments; but this was weak 
evidence. Furthermore, the sample size (log
2
) was asso-
ciated with smaller adjustments with both methods, the 
median journal rank (SJR) with smaller adjustment with 
Copas, and the number of studies was associated with 
more adjustment for regression, see online supplemental 
tables 13 and 14.
Adjustment by regression generally performed a 
stronger shrinkage of the treatment effects compared 
with the Copas selection model analysis. However, the 
adjustments were consistent between the two methods 
across the medical specialties and across meta- analyses 
(figure 5E,F). Compared with the regression- based 
method, the Copas method applied more zero or near- 
zero adjustment.
Change of evidence for treatment effects
The change of evidence via Bayes factor bounds in 5534 
meta- analyses was assessed by comparing the strength 
of the evidence after adjustment. The adjustment of 
the effects changed the overall evidence in many meta- 
analyses when effects were adjusted with regression but 
not so with Copas. The proportion of meta- analyses with 
very strong or decisive evidence for a treatment effect 
decreased from 32% down to 7% (regression) but only 
from 32% to 31% for Copas adjustments, see figure 5G.
DISCUSSION
Our study found that 19% from 5534 meta- analyses had 
evidence for small- study effects. This demonstrated that 
smaller studies reported larger effects, affecting 40% of 
the Cochrane systematic reviews. Most evidence for small- 
study effects was found in infectious diseases which also 
required larger adjustment compared with other special-
ties. Unsurprisingly, the number of studies in a meta- 
analysis was strongly associated with small- study effects 
as a higher number of studies increases statistical power 
to detect bias. Our results were consistent with the previ-
ously reported prevalence of asymmetry in 19% from a 
total of 366 meta- analyses15 with exactly the same inclu-
sion criteria. However, our dataset was 15 times larger as 
we also considered continuous outcomes which suggests 
a broader generalisability of our results.
Systematic assessment of meta- analyses with small- 
study effects suggested that publication bias may not be 
the main driver behind small- study effects. Only about 
4% of the 5534 meta- analyses demonstrated small- study 
effects with probable publication bias. It is worth noting 
that regression- based methods do not take into account 
the statistical significance of the study effects. Therefore, 
other reasons for smaller studies reporting larger effects 
must be considered: confirmation bias, lower- quality 
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switching or post hoc searches for statistical significance 
along with the incomplete reporting of statistically non- 
significant results.42 However, all these biases have the 
same effect on meta- analyses: they all lead to an exagger-
ation of the combined treatment effect.
Regression- based adjustment of meta- analyses changed 
the evidence of the treatment effects in many cases from 
decisive to weak while the Copas adjustment was more 
conservative with a majority of meta- analyses that received 
no or near zero adjustment. The two methods are funda-
mentally different: while regression is based on small- 
study effects, Copas analysis directly models publication 
bias and the selection process. Regression- based methods 
tend to overcorrect in some situations, for example, 
Figure 4 Enhanced funnel plots. Randomly picked examples of funnel plots with small- study effects (A); and small- study 
effects with probable publication bias (B). Small black circles are studies; statistically significant ones in red (based on original 
effect measure). The shades of grey are different levels of statistical significance (grey is p<0.05, light grey is p<0.01). The 
grey vertical line is the null, the dashed line the fixed effects, the dotted line the random effects estimate. The red diamont 
(regression) and green rectangle (Copas) are the adjusted effects, also as numbers (with 95% CI) at the bottom (unadjusted 
random effects estimate in black). The p value is from the asymmetry test by regression, k the number of studies. Above the 
funnel plots are the medical specialty, the outcome and comparison name; on the right the review id, meta- analysis id and the 
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when the adjusted effect turned out to be smaller than 
the smallest effect reported in a study. Future studies 
may apply shrinkage methods43 to regression- based 
adjustments.
We found that some medical specialties were more likely 
to report a statistically significant effect, for example, 
in anaesthesia and pain and skin and wounds while 
others were less likely to do so, for example, pregnancy 
and childbirth and neonatology. These findings were 
confirmed when looking at combined effects from meta- 
analyses. Reasons for this could be different study types 
and endpoints across the specialties, a higher number of 
true effects in a field, varying statistical power between 
fields or differences in reporting of statistically significant 
Figure 5 Adjustment of treatment effects. (A) Distribution of effect changes (Pearson’s r) from meta- analyses after adjustment 
by regression; (B) same for Copas adjustment. (C) Variables associated with effect changes, negative estimates reflect 
shrinkage of effects; (D) same for Copas adjustment. (E) Adjustment by regression versus Copas across specialties; (F) same 
across all meta- analysis. (G) Strengths of evidence against the null hypothesis of no treatment effect before (random effects 
meta- analysis) and after adjustment (regression and Copas). ENT, ear, nose and throat. SJR, Scimago journal rank. n.s., not 
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versus non- significant results. We replicated previous 
findings that studies with a statistically significant effect 
were more likely to be published in high ranking jour-
nals8 and also received a higher number of citations9 44 
which can indeed contribute to publication bias.45 We 
also showed that studies that are supposed to provide 
stronger evidence, such as RCTs, were less likely to report 
a statistically significant result.
Our study had some limitations. First, regression- based 
methods have been criticised to have a lack of statistical 
power46 and there are also other situations where regres-
sion methods (and also selection models) may fail: large 
heterogeneity, no significant studies or all studies are of 
similar sizes. Therefore, we followed available guidelines 
for inclusion criteria of suitable meta- analyses,14 15 among 
them including meta- analysis with low heterogeneity 
(I2 <50%) only. However, this can be criticised as selection 
bias can be introduced. For example, it has been shown it 
may be favouring small studies in meta- analyses.47 Further-
more, I2 is not an absolute measure of heterogeneity, that 
is, it does not tell us how much the effects actually vary.48 
Nevertheless, the application of I2 in our situation (to 
compare the amount of dispersion among studies within 
the CDSR) does not appear to be too unorthodox.49 Next, 
we only included 5534 (5.6%) of the 98 966 meta- analyses 
calculated; most were excluded because the number of 
studies was smaller than ten. However, this selection of 
meta- analyses may represent the more relevant medical 
interventions where many studies have been conducted. 
At the same time, it does not mean that the excluded meta- 
analyses with less than 10 studies are of less importance 
as many highly relevant interventions in disease preven-
tion and public health remain under- researched. In some 
cases, our meta- analyses do not exactly correspond to the 
ones performed in Cochrane Systematic Reviews as these 
also include unpublished findings; we excluded these as 
our aim was to assess publication bias when unpublished 
data is not considered. Altogether, systematic reviewers 
considered unpublished studies in 115 (11%) of the 1054 
meta- analyses with small- study effects, and in 26 (12%) of 
the 214 meta- analyses that have small- study effects with 
probable publication bias. A strength of our study was 
that we carefully labelled efficacy versus adverse event 
outcomes, however, we used an automatic approach by 
matching keywords which depended on the correct docu-
mentation of the comparison and outcome name by the 
systematic reviewers. The grouping of specialties is a 
limitation in our study as the grouping could have been 
done differently.
Around half of systematic reviews, in some specialties 
even less, do not evaluate publication bias and should 
do so more often.50 51 However, our findings suggest that 
large, potentially exaggerated effects from small studies 
give rise to greater concern than publication bias. The 
implications of this study are as follows: First, system-
atic reviewers should use advanced funnel plots with 
contours,52 regression tests or Copas selection models to 
investigate the robustness of their conclusions. Second, 
investigators should carefully assess the risk of bias and 
also provide individual patient data to combat publication 
bias.53 54 Finally, clinicians and patients should be cautious 
of small studies, especially when they report larger effects 
than larger studies, and to be attentive to sections on risk 
of reporting and publication bias in systematic reviews.
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